Anti-TNFα domain antibody construct CEP-37247: Full antibody functionality at half the size (Q34445142)

2 August 2017

title

Anti-TNFα domain antibody construct CEP-37247: Full antibody functionality at half the size (English)

1 reference

2 August 2017

1 reference

4

Teresa Domagala

1 reference

2 August 2017

Robert D Gay

1

1 reference

2 August 2017

Adam W Clarke

2

1 reference

2 August 2017

Zehra Elgundi

3

1 reference

2 August 2017

Raina J Simpson

5

1 reference

2 August 2017

Nga B Le

6

1 reference

2 August 2017

Anthony G Doyle

7

1 reference

2 August 2017

Phil A Jennings

8

1 reference

2 August 2017

publication date

1 November 2010

1 reference

2 August 2017

published in

Monoclonal Antibodies

1 reference

2 August 2017

volume

2

1 reference

2 August 2017

issue

6

1 reference

2 August 2017

page(s)

625-638

1 reference

The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions

2 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3011217

Trends in capacity utilization for therapeutic monoclonal antibody production

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3011217

Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3011217

Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3011217

Differences in binding and effector functions between classes of TNF antagonists

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3011217

Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3011217

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3011217

Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3011217

The benefit/risk profile of TNF-blocking agents: findings of a consensus panel

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3011217

Clinical pharmacokinetics of TNF antagonists: how do they differ?

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3011217

Immunogenicity of engineered antibodies

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3011217

Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3011217

Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3011217

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3011217

Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3011217

Analysis of changes during subclone development and ageing of human antibody-producing heterohybridoma cells by northern blot and flow cytometry.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3011217

Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3011217

Molecular cloning of the complementary DNA for human tumor necrosis factor

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3011217

Immunohistochemical demonstration of cytoplasmic and membrane-associated tumor necrosis factor in murine macrophages

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3011217

Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3011217

Evidence for the existence of two forms of membrane tumor necrosis factor: an integral protein and a molecule attached to its receptor

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3011217

A novel addition to the T cell repertory. Cell surface expression of tumor necrosis factor/cachectin by activated normal human T cells

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3011217

A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3011217

Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3011217

Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis

6 July 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.2.6.13493

Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.2.6.13493

Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.2.6.13493

Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.2.6.13493

Modulation of proinflammatory cytokine production in tumour necrosis factor-alpha (TNF-alpha)-transgenic mice by treatment with cells engineered to secrete IL-4, IL-10 or IL-13.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.2.6.13493

On the optimal ratio of heavy to light chain genes for efficient recombinant antibody production by CHO cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.2.6.13493

Crystal structure of HEL4, a soluble, refoldable human V(H) single domain with a germ-line scaffold

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.2.6.13493

The pharmacokinetics of interleukin-1 receptor antagonist in Chinese subjects with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.2.6.13493

Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.2.6.13493

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

21 January 2018

1 reference

12 December 2020

Adenovirus-based overexpression of tissue inhibitor of metalloproteinases 1 reduces tissue damage in the joints of tumor necrosis factor alpha transgenic mice

1 reference

12 December 2020

Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis

1 reference

12 December 2020

Physiological parameters in laboratory animals and humans

1 reference

12 December 2020

The TNF superfamily in 2009: new pathways, new indications, and new drugs

1 reference

12 December 2020

Identifiers

DOI

10.4161/MABS.2.6.13493

1 reference

2 August 2017

1 reference

2 August 2017

1 reference